Trius Therapeutics, Inc.

Trius Therapeutics, Inc. is a San Diego-based biopharmaceutical company dedicated to developing innovative antibiotic therapies for serious infections, particularly those caused by multi-drug resistant bacteria. Founded in 2004 in San Diego, US, Trius Therapeutics specializes in developing novel antibiotics. The company raised USD 25.

00 mn in a PIPE funding round in August 2010 from investors including Terrapin Opportunity, marking its total fundraising to USD 25. 00 mn. The company has engaged in nine deals with its most recent deal occurring on August 3, 2010. TriusRx offers medication management services, focusing on specialty pharmacy solutions for patients with complex health conditions.

Their services aim to enhance medication adherence and improve therapeutic outcomes by leveraging technology to streamline prescriptions and educate patients. TriusRx primarily serves healthcare providers, including hospitals and physicians, throughout the United States. In 2012, TriusRx reported revenue of USD 27. 18 mn, with an EBITDA of USD -55.

81 mn for the same year. The company's revenue model is business-to-business, relying on service agreements with healthcare providers, involving both subscription-based pricing and transactional fees for services rendered. Trius Therapeutics is poised for further growth through the development of new antibiotic therapies targeting resistant bacterial infections. The company plans to expand its presence beyond current markets, focusing on regions with a high prevalence of such infections.

The recent funding from the PIPE round will be utilized to support these new product developments and market expansion initiatives.